split-banner-image

ALTTO

Closed

ANZ 0702/BIG 2-06/N063D/EGF106708: ALTTO

BCT Study Chair:

Frances Boyle

A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.

international

8159

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

223

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

43

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

ALTTO PUBLICATIONS

2024

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

de Azambuja D, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang C-S, Burach NB, Bliss J, Ferro A, Gralow J, Kim S-B, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. ESMO Open. 2024; 9(11):https://doi.org/10.1016/j.esmoop.2024.103938, E-pub

2022

Characterization and validation of biologically-driven HER2-postiive breast cancer subgroups in the ALTTO and NeoALTTO clinical trials.

Rediti M, Venet D, Garcia AJ, Agbor-Tarh A, Maetens M, Vincent D, Jajjaj S, El-Abed S, Ueno T, Di Cosimo S, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothe F, Sotiriou C. San Antonia Breast Cancer Symposium. 2022; Abstract# P4-09-05, Abstract

Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study.

Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard K, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni & de Azambuja E. British Journal of Cancer. 2022; 1271799 – 1807, Published online 01 September 2022, Journal

PREDICT underestimates survival of patients of cancer with HER2-positive early stage breast cancer.

Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vincente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, Azambuja E, Lambertini M. npj Breast Cancer. 2022; 8(87):8, doi/10.1038/s41523-022-00452-8, Journal

Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial.

Rediti M, Venet D, Joaquin Garcia A, Agbor-tarh D, Maetens M, Vincent D, Majjaj S, El-Abed S, Liu MC, Di Cosimo S, Piccart M, Pusztai L, Loi S, Salgado RF, Viale G, Rothe F, Sotiriou C Annals of Oncology. 2022; 33(7):S55-S84, Abstract 139MO, Abstract

Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.

De Angelis C, Veeraraghavan J, Sethunath V, Ameye L, Paesmans M, El-Abed S, Choudhury A, Napoleone S, Chumsri S, Piccart-Gebhart MJ, Moreno-Aspitia A, Leonidas Gomez H, Viale G, Hilsenbeck SG, Rimawi MF, Osborne CK, Azambuja E, Schiff R. Journal of Clinical Oncology. 2022; 40(16 suppl):ASCO Abstract #522, Abstract

LOAD MORE

Institutions